XCSport体育
About Henlius
Company Profile
Corporate Culture
Honor
Board of Directors
XCSport体育:Management Team
Advisory Committee
Product
Marketed Products
XCSport体育:Products in R&D
XCSport体育:Clinical Trial
Science & Technology
R&D Result
Innovation Centre
Technology Platform
XCSport体育:Quality Management
XCSport体育:Manufacturing
Collaborations
Investor Relations
Information Disclosure
Corporate Governance
XCSport体育:Financial Reports
Stock Info
IR Calendar
Investor Presentation
Analyst Coverage
Contact Information
Media
XCSport体育:Press Release
XCSport体育:Multi-media
XCSport体育:Media Reports
Media Enquiry
Careers
Talent Philosophy
Staff Life
Training and Development
Job Opportunities
Contact Us
Contact Information
XCSport体育:Customer Message
Privacy
XCSport体育:Legal Statement
Compliance
EN
简体
EN
繁體
Home
XCSport体育:About Henlius
Company Profile
XCSport体育:Corporate Culture
Honor
Board of Directors
XCSport体育:Management Team
Advisory Committee
Product
XCSport体育:Marketed Products
XCSport体育:Products in R&D
XCSport体育:Clinical Trial
XCSport体育:Science & Technology
XCSport体育:R&D Result
XCSport体育:Innovation Centre
XCSport体育:Technology Platform
XCSport体育:Quality Management
Manufacturing
Collaborations
XCSport体育:Investor Relations
Information Disclosure
Listing Documents
Announcement & Circulars
Corporate Governance
Financial Reports
Stock Info
IR Calendar
Investor Presentation
Analyst Coverage
Contact Information
Media
Press Release
2025
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
XCSport体育:Multi-media
Company
Event
Popular Science
Media Reports
Media Enquiry
Careers
Talent Philosophy
Staff Life
Training and Development
Job Opportunities
XCSport体育:Contact Us
XCSport体育:Contact Information
XCSport体育:Customer Message
Privacy
XCSport体育:Legal Statement
XCSport体育:Compliance
搜索
Be the most trusted biotech company
Press Release
2025
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
Multi-media
Company
Popular Science
XCSport体育:Highlights
Download
Media Reports
XCSport体育:Media Enquiry
2023-12-27
Henlius and Fosun Pharma Entered into an Exclusive License Agreement for HANSIZHUANG in the US
2023-12-15
First Patient Dosed in a Phase 1 Clinical Study of Henlius Novel Anti-GARP and Anti-PD-1 Dual mAb Therapy in Australia
2023-12-15
HANSIZHUANG Granted Orphan Drug Designation in the European Union for Small Cell Lung Cancer
2023-12-09
First Patient Dosed in the Phase 1 Clinical Trial of Henlius’ Novel Anti-TIGIT Fc Fusion Protein HLX53
2023-12-05
Consul General in San Francisco visited Henlius US Innovation Centre
2023-12-02
The Phase 3 Clinical Study Results of Novel Anti-PD-1 mAb Serplulimab for the First-Line Treatment of ESCC Released at ESMO Asia Congress 2022
2023-12-02
The Updated Results of Phase 3 Clinical Study of Novel Anti-PD-1 mAb Serplulimab for the First-Line Treatment of ES-SCLC Released at ESMO Asia Congress 2022
2023-12-02
First Subject Dosed for Phase 1 Clinical Trial of Henlius’ Novel Anti-GARP mAb HLX60
2023-11-29
First Patient dosed in a Head-to-Head First-Line Bridging Study of HANSIZHUANG for ES-SCLC treatment in the US
1
2
3
...
7